Impact of Prior Abiraterone Acetate (Zytiga) on Subsequent Activity of Docetaxel (Chemotherapy) in Men with Metastatic Castration-Resistant Prostate Cancer

The explosion of new therapies for men with metastatic castration resistant prostate cancer (mCRPC) raises serious questions about the optimal sequencing of these new treatments as well as whether cross-resistance occurs between these drugs. It was recently reported that chemotherapy with docetaxel (D) is not effective in in men who did not have a ? [...]